Calutide 50mg Tablet

Calutide 50mg tablet is a prescription-based anticancer drug with an active ingredient called Bicalutamide. The doctor prescribes this drug for the treatment of advanced prostate cancer. Calutide 50mg tablet is given as androgen deprivation therapy, a combination of radiation and hormonal therapy. Androgen deprivation therapy drops down the levels of testosterone. The sensitivity of prostate cancer depends on androgen. Hence, the Calutide 50mg tablet aims to counteract the effect of androgen. It is recommended to take proper consultation with your doctor before taking it. Your doctor will decide the dosage and duration of taking this medicine. Taking it in the wrong way or overdosing can cause severe side effects. It is advised to use reliable methods of birth control and contraceptive pills to delay pregnancy while under treatment with Calutide 50mg tablet. Discuss with your healthcare expert the risks and benefits of taking this medicine if you want to conceive in the future.

Like other anticancer medicines, the Calutide 50mg Tablet has mild to severe side effects. These are undesired symptoms observed in the body after taking this tablet. Usually, they disappear with time as the body adjusts to the medicine. These adverse effects don't need special medical attention, but if you observe them continually, talk to your medical expert. Some of them are listed below:

Common side effects:

Anemia

Nausea & Vomiting
Constipation
Body pain
Rashes and skin allergy
Heavy urination during the night
Low sex drive
Loss in appetite
Edema
Weakness & dizziness
Breathlessness
Hair loss
Hot flushes

Severe side effects:
Heart problem
blood in urine
Difficulty in urine
Increased blood sugar level
Increase in liver enzyme level

Calutide 50mg Tablet is a prescription-based anticancer drug that should be administered orally. It is advised to take this tablet after consulting your healthcare expert.

Calutide 50mg Tablet belongs to the drug class of non-steroidal anti-androgens. This medicine binds to cytosol androgen receptors and inhibits the effect of androgen hormones. It blocks the interaction of androgen receptors with testosterone and dihydrotestosterone hormones. In such a way, it shrinks the tumors and slows down the multiplication of the cancer cells.

It is advised not to miss any scheduled dosage of Calutide 50mg Tablet. In case you miss a dose, consult your doctor immediately.

Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

Using Calutide 50mg Tablet causes light sensitivity. Use sunscreen before exposing to direct sunlight.

It is recommended to inform your doctor if you take any prescribed and non-prescribed medications, nutritional or vitamin supplements, or herbal products. These drugs can interact with Calutide 50mg Tablet and may result in some severe side effects.

Your healthcare provider will decide how much you take and how often you need Calutide 50mg Tablet. You are advised to follow the prescription strictly.

Your healthcare expert must measure your blood sugar & pressure, and liver function tests at regular intervals. Taking the Calutide 50mg Tablet can cause fluctuations in their levels.

Boccardo, F., Rubagotti, A., Battaglia, M., Di Tonno, P., Selvaggi, F. P., Conti, G. & Montefiore, F. (2025). Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. Journal of Clinical Oncology, 23(4), 808-815.
Boccardo, F., Rubagotti, A., Conti, G., Potenzoni, D., Manganelli, A., & Monaco, D. D. (2024). Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. Cancer chemotherapy and pharmacology, 56(4), 415-420.
Kotake, T., Usami, M., Isaka, S., Shimazaki, J., Nakano, E., Okuyama, A., & Tsukagoshi, S. (2025). Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer. Hinyokika Kiyo. Acta Urologica Japonica, 42(2), 157-168.
Kotake, T., Usami, M., Isaka, S., Shimazaki, J., Oishi, K., Yoshida, O., & Taguchi, T. (2023). Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer. Hinyokika Kiyo. Acta Urologica Japonica, 42(2), 143-153.
Kunath, F., Grobe, H. R., Ruecker, G., Motschall, E., Antes, G., Dahm, P. & Meerpohl, J. J. (2024). Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database of Systematic Reviews, (6).
Saltzstein, D., Sieber, P., Morris, T., & Gallo, J. (2025). Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate cancer and prostatic diseases, 8(1), 75-83.